Promis Neurosciences INC Schedule 13G passive stakes

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 7.66% of Promis Neurosciences Inc. common shares.

Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. has updated its Schedule 13G filing, reporting beneficial ownership of 7.8% of ProMIS Neurosciences, Inc. common stock as of June 30, 2026.

Wellington Management Group LLP and its affiliates have reported a change in their beneficial ownership of ProMIS Neurosciences, Inc. common stock, now holding 7.8% of the class.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 9.99% of Promis Neurosciences Inc. common shares.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 10% of ProMIS Neurosciences, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 14.4% of Promis Neurosciences Inc. common shares as of March 31, 2026.

Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. has reported a 9.99% beneficial ownership stake in ProMIS Neurosciences, Inc. common stock.

Deep Track Capital and its affiliates have reported a 9.99% beneficial ownership stake in ProMIS Neurosciences Inc., including common shares and exercisable warrants.

Sphera Funds Management and its affiliates reported a 7.78% beneficial ownership stake in ProMIS Neurosciences Inc., including common shares and warrants, following a recent reverse stock split.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 5.53% beneficial ownership in Promis Neurosciences Inc.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a 9.99% beneficial ownership stake in ProMIS Neurosciences Inc. through common shares and exercisable warrants.

Sphera Funds Management Ltd. and its affiliates have reported a 5.51% beneficial ownership stake in ProMIS Neurosciences Inc., totaling 3,122,090 common shares.

Jeremy M. Sclar and affiliated entities have significantly increased their beneficial ownership in ProMIS Neurosciences Inc. to 16.9% through a series of private placements and warrant exercises.

Great Point Partners, LLC and its principals, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a 9.99% beneficial ownership stake in ProMIS Neurosciences Inc.

Michael S. Gordon and Title 19 Promis have increased their beneficial ownership in ProMIS Neurosciences Inc. to 9.0% through a series of share and warrant acquisitions.

Ally Bridge Group entities and Fan Yu have disclosed a beneficial ownership of 11.8% in ProMIS Neurosciences Inc., totaling 6,058,738 common shares.

Shaf QIC LLC and Jonathan Shafmaster have disclosed a 10.01% beneficial ownership stake in ProMIS Neurosciences Inc., comprising common shares and warrants.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 7.14% of PROMIS NEUROSCIENCES INC.'s common shares as of March 31, 2025.

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 7.68% in PROMIS NEUROSCIENCES INC., totaling 2,509,977 common shares.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly disclosed a beneficial ownership of 9.99% in ProMIS Neurosciences Inc., totaling 3,334,520 common shares.